Breast Cancer Market Report 2025 (Global Edition)

Global Breast Cancer Market Report 2025 Market Size Split by Type Outlook: (Invasive Ductal Carcinoma, Invasive Lobular Carcinoma), by Treatment Outlook: (Chemotherapy, Surgery & Radiation Therapy, Ta...

Breast Cancer Market Report Description

We have various report editions of Breast Cancer Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Competitive Landscape of the Breast Cancer Market

The breast cancer market's competitive landscape features major pharmaceutical companies, biotech firms, and emerging players focusing on innovative therapies and diagnostic tools. Key players include Roche, Novartis, Pfizer, and AstraZeneca, known for extensive research and development in targeted and biologic therapies. Partnerships, acquisitions, and clinical trials drive competition as companies seek to enhance treatment efficacy and reduce side effects. Additionally, advancements in personalized medicine and precision diagnostics intensify competition, with companies striving to meet the demand for effective, patient-centered treatments.

In June 2023, Novartis reported that Kisqali significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer.

(Source:https://www.novartis.com/news/media-releases/fda-approves-novartis-kisqali-reduce-risk-recurrence-people-hrher2-early-breast-cancer#:~:text=The%20approval%20is%20based%20on,EBC%20treated%20with%20adjuvant%20Kisqali)

In February 2024, Pfizer Oncology hosted Innovation Day, highlighting its fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth.

(Source:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-oncology-hosts-innovation-day-highlighting-fully)

In Dec 2023, Stratipath and Proscia announced a partnership, paving the way to bring relapse risk prediction to more breast cancer patients.

(Source:https://proscia.com/press-releases/stratipath-and-proscia-announce-partnership-paving-the-way-to-bring-relapse-risk-prediction-to-more-breast-cancer-patients/#:~:text=STOCKHOLM%20%E2%80%93%20December%205%2C%202023%20%E2%80%93,suitable%20treatment%20path%20for%20more)

Top Companies Market Share in Breast Cancer Industry: (In no particular order of Rank)

• Mylan Laboratories
• AstraZeneca
• Celltrion
• Bristol-Myers Squibb
• FRESENIUS KABI
• Eisai Co. Ltd
• Baxter Healthcare Corporation
• GlaxoSmithKline
• Pfizer Inc.
• Halozyme Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Breast Cancer Market

Which Region Dominates the Breast Cancer Market in 2024?

According to Cognitive Market Research, North America is anticipated to dominate the breast cancer market in 2024, driven by its advanced healthcare infrastructure, significant investment in research and development, and a robust network of specialized cancer treatment centers. The region benefits from a high prevalence of breast cancer awareness campaigns, leading to increased screening and early detection. Moreover, favorable reimbursement policies facilitate patient access to innovative therapies, including targeted and biologic treatments. The presence of leading pharmaceutical companies in the United States fosters continuous innovation, positioning North America as a frontrunner in breast cancer care and treatment advancements.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is expanding at the fastest CAGR in the breast cancer market, fueled by increasing awareness of breast cancer and improving healthcare infrastructure. Rapid urbanization and rising disposable incomes contribute to greater access to medical facilities and treatments. Governments are implementing initiatives to enhance screening programs, which drive early detection and intervention. The growing prevalence of breast cancer, coupled with a rising patient population, further propels market growth. Significant investments in biotechnology and pharmaceuticals by both local and international companies are fostering innovation in treatment options, strengthening the region's position in the global breast cancer market.

The current report Scope analyzes Breast Cancer Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Breast Cancer Market Analysis

According to Cognitive Market Research, the global Breast Cancer market size was estimated at USD 33521.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 13408.60 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Breast Cancer market with a market size of USD 1057670.43 million in 2024 and is projected to grow at a CAGR of 7.8% during the forecast period. Growth is driven by advanced healthcare infrastructure and substantial cancer research funding.
• The Canada Breast Cancer market had a market share of USD 1609.03 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. Rising breast cancer awareness and accessible screening programs enhance market growth.
• The Mexico Breast Cancer market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 1220.18 million in 2024.

Europe Breast Cancer Market Analysis

According to Cognitive Market Research, the global Breast Cancer market size was estimated at USD 33521.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 10056.45 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.3% from 2024 to 2031.

• The United Kingdom Breast Cancer market had a market share of USD 1689.48 million in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period. Strong government support and extensive screening initiatives contribute to market expansion.
• The France Breast Cancer market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 925.19 million in 2024.
• According to Cognitive Market Research, the German Breast Cancer market size was valued at USD 1991.18 million in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period. High demand for innovative therapies and robust healthcare support fuels growth.
• The Italy Breast Cancer market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 864.85 million in 2024.
• The Russia Breast Cancer market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 1558.75 million in 2024.
• The Spain Breast Cancer market is projected to witness growth at a CAGR of 7.4% during the forecast period with a market size of USD 824.63 million in 2024
• The Luxembourg Breast Cancer market is projected to witness growth at a CAGR of 8.4% during the forecast period, with a market size of USD 311.75 million in 2024.
• The Portugal Breast Cancer market is projected to witness growth at a CAGR of 8.1% during the forecast period, with a market size of USD 211.19 million in 2024.
• The Greece Breast Cancer market is projected to witness growth at a CAGR of 8.6% during the forecast period, with a market size of USD 120.68 million in 2024.
• The Rest of Europe's Breast Cancer market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 1558.75 million in 2024.

Asia Pacific Breast Cancer Market Analysis

According to Cognitive Market Research, the global Breast Cancer market size was estimated at USD 33521.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 7709.95 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.8% from 2024 to 2031.

• According to Cognitive Market Research, the China Breast Cancer market size was valued at USD 3469.48 million in 2024 and is projected to grow at a CAGR of 11.3% during the forecast period. Increasing patient pool and healthcare investments drive significant market growth.
• The Japan Breast Cancer market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 1063.97 million in 2024.
• The India Breast Cancer market had a market share of USD 925.19 million in 2024 and is projected to grow at a CAGR of 13.6% during the forecast period. Growing awareness and improving healthcare infrastructure promote market expansion.
• The South Korean Breast Cancer market is projected to witness growth at a CAGR of 10.9% during the forecast period, with a market size of USD 7770.40 million in 2024.
• The Australian Breast Cancer market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD 400.92 million in 2024.
• The South East Asia Breast Cancer market is projected to witness growth at a CAGR of 12.8% during the forecast period, with a market size of USD 531.99 million in 2024.
• The Rest of Asia Pacific Breast Cancer market is projected to witness growth at a CAGR of 11.6% during the forecast period, with a market size of USD 547.41 million in 2024.

South America Breast Cancer Market Analysis

According to Cognitive Market Research, the global Breast Cancer market size was estimated at USD 33521.5 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 1676.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Breast Cancer market size was valued at USD 717.36 million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period. Expanded healthcare access and public awareness campaigns support market growth.
• Argentina's Breast Cancer market had a market share of USD 281.58 million in 2024 and is projected to grow at a CAGR of 10.1% during the forecast period. Enhanced early detection and treatment access contribute to growth in the market.
• Colombia Breast Cancer market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 149.17 million in 2024.
• Peru Breast Cancer market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD 137.44 million in 2024.
• Chile Breast Cancer market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 120.68 million in 2024.
• The Rest of Latin America's Breast Cancer market is projected to witness growth at a CAGR of 8.3% during the forecast period, with a market size of USD 269.85 million in 2024.

Middle East Breast Cancer Market Analysis

According to Cognitive Market Research, the global Breast Cancer market size was estimated at USD 33521.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 670.43 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.5% from 2024 to 2031..

• The GCC Countries Breast Cancer market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 286.94 million in 2024. Government investments in healthcare infrastructure and awareness initiatives boost growth.
• The Egypt Breast Cancer market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 70.40 million in 2024.
• The South Africa Breast Cancer market is projected to witness growth at a CAGR of 10.5% during the forecast period, with a market size of USD 105.93 million in 2024. Rising cancer rates and improving healthcare facilities support market expansion.
• The Turkey Breast Cancer market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 57.66 million in 2024.
• The Nigeria Breast Cancer market is projected to witness growth at a CAGR of 8.6% during the forecast period, with a market size of USD 70.40 million in 2024.
• The Rest of the MEA Breast Cancer market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 79.11 million in 2024.

Breast Cancer Market Analysis

How are Segments Performing in the Global Breast Cancer Market?

Breast Cancer Market Type Segment Analysis

According to Cognitive Market Research, Invasive ductal carcinoma (IDC) commands the largest share in the breast cancer market, attributed to its high prevalence and wide recognition among oncologists and healthcare providers. Representing approximately 80% of diagnosed cases, IDC begins in the milk ducts and invades surrounding tissues, making early detection critical. Its dominance in the market is further driven by the extensive availability of tailored treatment protocols, including chemotherapy, targeted therapy, and hormonal interventions. With significant advancements in diagnostic tools and awareness campaigns, healthcare systems have prioritized managing IDC, solidifying its leading role within the type segment.

Invasive lobular carcinoma (ILC) is emerging as the fastest-growing segment, fueled by rising awareness of its unique presentation and challenges in detection. Unlike IDC, ILC originates in the milk-producing glands and often presents without forming a palpable lump, necessitating advanced imaging techniques for accurate diagnosis. Its growth trajectory is underpinned by advancements in personalized medicine and the development of novel therapeutic approaches. Increasing research into its distinct molecular pathways has spurred interest in targeted therapies, promising improved outcomes. The demand for precision medicine tailored to ILC's unique characteristics is expected to propel significant growth within this segment.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Breast Cancer Industry. Request a Free Sample PDF!

Breast Cancer Market Treatment Segment Analysis

According to Cognitive Market Research, the breast cancer market's treatment segment encompasses various modalities, including chemotherapy, targeted therapy, hormone therapy, biologic therapy, and surgery. Chemotherapy remains the largest segment, primarily due to its widespread application in treating various stages of breast cancer. This conventional approach employs cytotoxic agents to eliminate rapidly dividing cancer cells, often used in conjunction with other therapies to enhance efficacy. Despite the emergence of innovative treatments, chemotherapy continues to play a pivotal role in treatment regimens, especially for aggressive cancer types. Its established effectiveness and the extensive experience of oncologists with these protocols contribute to its dominance in the market.

Targeted therapy is recognized as the fastest-growing segment within the breast cancer treatment market, driven by advancements in personalized medicine. This innovative approach focuses on specific molecular targets associated with cancer cells, leading to more effective and less toxic treatment options. Targeted therapies, such as HER2 inhibitors and hormone receptor modulators, have transformed treatment landscapes, particularly for HER2-positive and hormone receptor-positive breast cancers. The increasing prevalence of genetic testing and biomarker identification is further propelling this segment's growth, enabling tailored treatments that improve patient outcomes. As research continues to unveil new targets, the potential for this segment to expand remains robust, positioning it at the forefront of breast cancer management.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Breast Cancer Cancer Type Outlook: Segment Analysis

Breast Cancer Market Cancer Type Segment Analysis

According to Cognitive Market Research, the breast cancer market can be segmented by cancer type into hormone receptor-positive, HER2-positive, and triple-negative breast cancer. Among these, hormone receptor-positive breast cancer represents the largest segment, accounting for a substantial share of the market. This category is characterized by tumors that grow in response to hormones like estrogen and progesterone. The increasing prevalence of hormone receptor-positive breast cancer can be attributed to rising obesity rates and sedentary lifestyles, which are known risk factors. The availability of targeted therapies, such as aromatase inhibitors and selective estrogen receptor modulators, further supports market growth within this segment.

The fastest-growing segment within the breast cancer market is HER2+ breast cancer. This category involves tumors that overexpress the HER2+, leading to aggressive tumor growth. Significant advancements in targeted therapies, particularly the introduction of monoclonal antibodies and tyrosine kinase inhibitors, have dramatically improved treatment outcomes for patients with HER2+ breast cancer. Increased awareness of genetic testing and the importance of personalized medicine are driving demand for effective therapies in this segment. As healthcare providers prioritize early detection and treatment strategies, the HER2+ segment is poised for remarkable growth in the coming years.

• Hormone Receptor
• HER2+

Breast Cancer End-user Outlook: Segment Analysis

Breast Cancer Market End-user Segment Analysis

According to Cognitive Market Research, the breast cancer market comprises several end-user segments, including hospital pharmacies, private pharmacies, and clinics. Hospital pharmacies represent the largest segment, primarily due to their comprehensive cancer treatment facilities and specialized staff. These pharmacies offer a wide range of oncology drugs, personalized treatment plans, and access to clinical trials, enabling patients to receive tailored therapies. Their integration within healthcare systems ensures immediate access to medication, vital for effective breast cancer management. The presence of multidisciplinary teams within hospitals also enhances patient care, contributing to a more robust and supportive treatment environment.

The fastest-growing segment within the breast cancer market is private pharmacies, driven by increasing patient demand for convenient access to medications and personalized healthcare solutions. These pharmacies often provide a more personalized experience, focusing on individual patient needs, which fosters loyalty and trust. The rise of telepharmacy services and home delivery options enhances accessibility, making it easier for patients to obtain their prescriptions. Furthermore, private pharmacies are adapting to the market's evolving landscape by offering innovative products and services, such as genetic testing and counseling, which support personalized treatment strategies. This adaptability positions private pharmacies as key players in the breast cancer treatment ecosystem.

• Hospital Pharmacies
• Private Pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion